Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody

DOI Web Site Web Site 参考文献252件
  • Hayashi Hiroaki
    Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
  • Ishii Makoto
    Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
  • Hasegawa Yoshinori
    Department of Respiratory Medicine, Nagoya University Graduate School of Medicine National Hospital Organization Nagoya Medical Center
  • Taniguchi Masami
    Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital

この論文をさがす

説明

<p>Characteristic symptoms of NSAID-exacerbated respiratory disease (N-ERD) include asthma, chronic eosinophilic rhinosinusitis with nasal polyposis, cysteinyl LT (CysLT) overproduction and NSAIDs hypersensitivity. Some N-ERD patients present with episodic treatment-resistant extra-respiratory symptoms (CysLT-associated coronary artery vasospasm, gastroenteritis, or skin rash). Even when using standard treatments for respiratory and extra-respiratory symptoms, including systemic corticosteroids and aspirin desensitization, it is difficult to control the clinical symptoms and severe type 2 inflammation involved with mast cells, eosinophils, ILC2s, and platelet activation. Few treatment options are applicable in a clinical setting. Therefore, identifying effective treatments is essential for managing N-ERD patients who suffer from these conditions. Our previous observational study demonstrated 12-month omalizumab treatment of N-ERD was clinically effective against respiratory symptoms. Despite the remaining eosinophilia, omalizumab significantly reduced urinary LTE4 and PGD2 metabolites to near normal levels at steady state. Based on the preliminary study, we demonstrated that omalizumab induced tolerance to aspirin in N-ERD patients 3 months after therapy initiation and suppressed activation of mast cells during 24 h of initiation in a randomized manner. Moreover, omalizumab had significant efficacy against extra-respiratory symptoms at baseline (lacking aspirin exposure) as well as throughout aspirin challenge. This review addresses the latest discoveries related to N-ERD pathogenesis and the significant effectiveness of omalizumab on N-ERD as a mast cell stabilizer. Our findings regarding omalizumab-associated mast cell inhibitory effects are indirect evidence that mast cell dysregulation and, possibly, IgE are pivotal components of N-ERD.</p>

収録刊行物

参考文献 (252)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ